Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack | Zendy

Lawrence H. Young | Zendy; Catherine M. Viscoli | Zendy; Jeptha P. Curtis | Zendy; Silvio E. Inzucchi | Zendy; Gregory G. Schwartz | Zendy; Anne M. Lovejoy | Zendy; Karen L. Furie | Zendy; Mark Gorman | Zendy; Robin Conwit | Zendy; J. Dawn Abbott | Zendy; Daniel Jacoby | Zendy; Daniel M. Kolansky | Zendy; Steven Pfau | Zendy; Frederick S. Ling | Zendy; Walter N. Kernan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack

Author(s) -

Lawrence H. Young,

Catherine M. Viscoli,

Jeptha P. Curtis,

Silvio E. Inzucchi,

Gregory G. Schwartz,

Anne M. Lovejoy,

Karen L. Furie,

Mark Gorman,

Robin Conwit,

J. Dawn Abbott,

Daniel Jacoby,

Daniel M. Kolansky,

Steven Pfau,

Frederick S. Ling,

Walter N. Kernan

Publication year - 2017

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.116.024863

Subject(s) - medicine , cardiology , stroke (engine) , ischemic stroke , transient (computer programming) , ischemia , computer science , operating system , mechanical engineering , engineering

Insulin resistance is highly prevalent among patients with atherosclerosis and is associated with an increased risk for myocardial infarction (MI) and stroke. The IRIS trial (Insulin Resistance Intervention after Stroke) demonstrated that pioglitazone decreased the composite risk for fatal or nonfatal stroke and MI in patients with insulin resistance without diabetes mellitus, after a recent ischemic stroke or transient ischemic attack. The type and severity of cardiac events in this population and the impact of pioglitazone on these events have not been described.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research